Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
TSH (thyroid-stimulating hormone): Thyroid dysfunction is common in GLP-1 candidate populations and can significantly confound both weight response and metabolic improvement if left unaddressed
Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists
_(1)44368228eb044342af44e53832b68ca4.png)
~22% Average body weight lost with tirzepatide over 72 weeks NEJM SURMOUNT-1 Trial Dual-Action Targets both GLP-1 and GIP receptors for stronger results Clinical mechanism Dual-action: targets GLP-1 + GIP receptors May produce greater weight loss results Stronger appetite suppression reported Significantly reduces "food noise" Great for patients wanting maximum results Starting at $269/mo Physician-reviewed Not sure which is right for you
Collaboration between healthcare professionals and the food industry is essential to supporting consumers on GLP-1 medications
